The drug-eluting stent market is anticipated to grow at a CAGR of 8.20% from US$11.499 billion in 2025 to US$17.049 billion ...

Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD.

Discover how IVBT impacts long-term outcomes in complex in-stent restenosis—read the full report for key clinical insights.

R3 Vascular announced that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting ...

It is quite clear that the Gujarat government’s rather ill-informed decision will penalise Indian manufacturers who today hold over 73% of the domestic market and export over 5 lakh stents annually to ...

Coronary stents—small, mesh-like tubes inserted into narrowed or blocked arteries—are essential in restoring blood flow following angioplasty and are a key treatment for CAD. Among these, drug-eluting ...

Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target vessel revascularization when compared with bare-metal stents. However, drug-eluting stents may ...

Y. Vijayachandra Reddy, senior consultant interventional cardiologist at Apollo Hospitals, Chennai, discusses personalized ...

Drug-Eluting Stents (DES).” Under the new rules (now scrapped), the stents approved by the USFDA were capped at ₹25,000, while those approved by domestic regulators were capped at ₹12,000.

The global peripheral vascular devices market, valued at USD 4.7 billion in 2022, is projected to expand at a robust CAGR of 6.6%, reaching USD 8.9 billion by 2032, according to Future Market Insights ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.